To further improve the yield and enantiomeric ratio, the optimization of the reaction conditions was carried out by screening different solvents, additives and varying the temperature using catalyst C-2 (Table 2 ). This time a one-pot addition/acylation reaction was carried out in order to obtain the enolacetate 6a, whose enantiomers could be easily resolved by HPLC. After screening various solvents (entries 1-9), it was found that no other solvent provide better er-values than dichloromethane. An increase in the er-value of 6a was observed by lowering the temperature to -20 ˚C (entry 10). Moreover, the presence of 4 Å molecular sieves (MS) also led to an increase in the enantioselectivity (entry 11). Further lowering of the temperature and the reducing catalyst loading, however, led to a lower reaction rate and hence lower yields (entries 12 and 13). Based on these optimization studies, best reaction condition for this transformation include 1 mol% of C-2 in dichloromethane at -48 ˚C and 4 Å MS as an additive, providing the desired product 5a with 99% yield and 98.5:1.5 er (entry 14). a Reaction conditions: 0.20 mmol of 1a, 0.22 mmol of 4a, 1 mol% of C-2 in 1.0 mL of solvent. b Yield of isolated product 6a after column chromatography. c The enantiomeric ratios were determined by HPLC analysis on a chiral stationary phase. e Yield of the non-acylated product 5a. f 0.5 mol% of C-2 was used. After the optimization, we then focused towards the substrate scope for the squaramide C-2 catalyzed Mannich addition of the pyrazolones 1 to the imines 4 ( Table 3 ). The variation in the Nsubstituent (R 1 ) of 1 showed that the aryl group bearing electron-withdrawing and electron-donating group led to the formation of the corresponding adducts 5b-d in high yields and very good er-values.
A N-methyl group is also well tolerated to provide the desired product 5e in 89% yield and good er of 91:9. Various alkyl substituents (R 2 ) at the C-3 position of the pyrazolone 1 also worked very well in terms of er-values of the products 5f-h, but the increase in steric bulk, the yield decreased to some extent. A pyrazolone bearing a trifluoromethyl group at the C-3 position led to the formation of the desired product 5i in 71% yield, however, the er could not be determined by HPLC.
CONCLUSION
In conclusion, we have synthesized pyrazolone derived N-Boc ketimines and utilized these new electrophiles in the organocatalytic asymmetric Mannich-type addition of pyrazolone derivatives. With a low loading of the squaramide C-2 and C-5 both enantiomers of the corresponding amino-bispyrazolones with one and two tetrasubstituted stereocenters were synthesized in good to excellent yields and stereoselectivities for a wide range of substrates. In addition, the one-pot organocatalytic enantioselective Mannich addition and base mediated diastereoselective α-halogenation also worked efficiently to provide the corresponding bis-pyrazolones bearing two adjacent tetrasubstituted halo and amino stereogenic centers.
EXPERIMENTAL SECTION
General Method. All reactions were performed in oven-dried glassware. Analytical TLC were carried out using SIL G-25 UV254 from Machery & Nagel and visualized with ultraviolet radiation at 254 nm.
1 H and 13 C NMR spectra were recorded in CDCl 3 at ambient temperature on Varian Innova 400 or Innova 600 instruments. Chemical shifts for 1 H NMR and 13 C NMR spectra were reported in parts per million (ppm), with coupling constants given in Hertz (Hz). The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet and br = broad signal. The assignment of the exact numbers of carbon atoms in the bis-aminopyrazolone products was not possible, hence only the number of signals seen in the 13 C NMR spectra are written. It is assumed that this problem is due to a possible keto-enol tautomerization or the restricted rotation. Mass spectra were recorded with the spectrometer SSQ 7000 from Finnigan at 70 eV, whereas HRMS data (ESI) were collected with a ThermoFisher Scientific LTQ-Orbitrap XL apparatus. IR spectra were taken on a PerkinElmer Spectrum 100 FT-IR spectrometer. Analytical HPLC was carried out either on a Hewlett-Packard 1050 series instrument or Agilent 1100 instrument using chiral stationary phases. Analytical SFC was carried out on a Thar SFC Waters Method Station II instrument using chiral stationary phases. The diasteromeric ratio was determined by the 1 H NMR 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Unless specified, the starting materials and reagents were purchased directly from the commercial suppliers and used without further purification. The squaramides C1 to C7 16 and the benzyl cuperine C-9 17 were synthesized using known literature procedures.
General procedure for the synthesis of pyrazolone derived phenyl ketimines 2. Nitrosobenzene (25.0 mmol, 1.0 equiv.) and K 2 CO 3 (0.2 equiv.) were added to a solution of pyrazolone derivative 1 (25.0 mmol, 1.0 equiv.) in MeOH (0.6 M) at room temperature. The reaction mixture was then refluxed for 3 hours. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate. The organic layer was washed three times with water, once with brine and then dried over anhydrous MgSO 4 . After evaporation of ethyl acetate under reduced pressure, the crude product was purified by flash column chromatography (n-pentane/diethyl ether, 3:1) to afford the ketimine product 2. -2-phenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2a) : red solid; 3.16 g, 48%; mp = 102 -104 ˚C; IR (capillary) 3060, 2287, 2084, 1937, 1664, 1587, 1488, 1412, 1360, 1297, 1132, 998, 911, 831, 744, 687 150.8, 146.3, 137.7, 129.0 (2C), 128.7 (2C), 125.6, 121.8 (2C), 118.5 (2C), 118.4, 12.4; MS (EI) -5-methyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2b) : red solid; 3.64 g, 49%; mp = 121 -123 ˚C; IR (capillary) 3461, 2993, 2678, 2338, 2093, 1902, 1716, 1577, 1479, 1305, 1105, 994, 820 : red solid; 3.32 g, 48%; mp = 75 -77 ˚C; IR (capillary) 3354, 2934, 2702, 2339, 2092, 1907, 1690, 1497, 1306, 1129, 993, 774, : red solid; 3.19 g, 46%; mp = 94 -96 ˚C; IR (capillary) 3460, 2970, 2663, 2336, 2094, 1912, 1728, 1589, 1479, 1341, 1225, 1117, 1037, 919, 836, 755 5, 152.0, 151.3, 146.5, 137.8, 129.0 (2C), 128.7 (2C), 128.4, 125.5, 121.4 (2C), 118.4 (2C) 2957, 2340, 2095, 1925, 1717, 1590, 1479, 1375, 1304, 1213, 1108, 963 4, 152.0, 150.8, 146.7, 137.7, 128.9 (2C), 128.7 (2C), 127.8, 125.4, 120.3 (2C) General procedure for the synthesis of pyrazolone-derived ketones 3. The ketimine 2 (10 mmol) was dissolved in THF (0.13 M) and the aqueous HCl (2.0 N) solution (25 mL) was added to it at room temperature. The progress of the reaction was monitored on TLC. After completion of the reaction, the mixture was diluted with water. The organic layer was extracted three times with dichloromethane and the combined organic layers were dried over anhydrous MgSO 4 . The solvent was removed under reduced pressure and the crude product was directly purified by flash column chromatography (nhexane/EtOAc, 1:1) to afford the desired product 3. -1-phenyl-1H-pyrazole-4,5-dione (3a) : red solid; 1.58g, 84%; mp = 119 -121 ˚C; IR (capillary) 3083, 2078, 1765, 1722, 1591, 1492, 1434, 1416, 1370, 1279, 1151, 1086, 1039, 972, 913, 849 -pyrazole-4,5-dione (3b) : red solid; 1.71 g, 77%; mp = 157 -159 ˚C;
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IR (capillary) 3106, 2060, 1772, 1714, 1591, 1491, 1432, 1402, 1369, 1309, 1284, 1166, 1090, 1048, 1006, 855, 825, 736, 687 General procedure for the synthesis of pyrazolone-derived N-Boc ketimine 4. The tertbutyl(triphenylphosphoranylidene)acetate (1.1 equiv.) was added to a solution of the pyrazolonederived ketone 3 (0.5 mmol) in 1,4-dioxane (0.2 M) at room temperature and the mixture was refluxed for 3-3.5 hours. After completion of the reaction, the solvent was removed under reduced pressure and the crude product was directly purified by flash column chromatography (n-pentane/diethyl ether, 1:1)
to afford the desired N-Boc ketimine 4.
tert- tert-Butyl (1-(4-chlorophenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4- tert-Butyl (1-(4-methylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene) -carb-amate (4c):
1.13 g, 75%; orange solid; mp = 170-172 °C; IR (capillary) 2986, 1727, 1612, 1517, 1440, 1368, 1313, 1249, 1147, 1036, 988, 880, 818, 772 General procedure for the synthesis of 5 and ent-5. In a 10 mL reaction tube equipped with a magnetic stirring bar, the imine 4 (1.1 equiv., 0.22 mmol), catalyst C-2 or C-5 (2 mol%) and 4 Å molecular sieves (50 mg) were stirred in dichloromethane (1.0 mL) at -48 °C. After 10 minutes, pyrazolone 1 (1.0 equiv. 0.2 mmol) was added and the stirring was continued for 24 hours at the same temperature. The reaction mixture was kept at room temperature for 1 hour and the crude product was directly purified by flash column chromatography (n-hexane/EtOAc, 1:1) to afford the products 5 or
tert-Butyl (S)- (5-hydroxy-3,3'-dimethyl-5'-oxo-1,1'-diphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 1, 162.1, 161.3, 155.9, 146.8, 139.4, 136.3, 130.4, 130.0, 129.9, 128.3, 126.3, 123.0, 120.0, 119.1, 94.9, 81.7, 66.4, 28.6, 13.5, 11.7 tert-Butyl (S)- (1-(2-chlorophenyl)-5-hydroxy-3,3'-dimethyl-5'-oxo-1'-phenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol [4,4'-bipyrazol (5-hydroxy-1,3,3'-trimethyl-5'-oxo-1'-phenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 4, 155.9, 143.8, 139.4, 129.9, 126.3, 126.1, 120.1, 119.1, 93.9, 81.6, 66.5, 30.4, 28.5, 28.4, 13 3-ethyl-5-hydroxy-3'-methyl-5'-oxo-1,1'-diphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 4, 162.8, 161.7, 155.9, 152.2, 139.4, 136.4, 130.4, 129.9, 128.5, 126.4, 123.6, 120.1, 119.1, 94.2, 81.7, 66.5, 28.5, 19.9, 13.4, 12.7 (5-hydroxy-3'-methyl-5'-oxo-1,1'-diphenyl-3-propyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 8, 155.8, 150.6, 139.4, 136.3, 130.4, 129.0, 129.9, 128.5, 126.3, 123.5, 119.8, 118.9, 94.3, 81.7, 66.7, 28.5, 28.4, 24.2, 22.7, 14.1, 13.3; MS (EI) (5-hydroxy-3-isopropyl-3'-methyl-5'-oxo-1,1'-diphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 5, 162.7, 161.8, 156.4, 155.8, 139.4, 136.3, 130.7, 129.9, 128.8, 126.4, 124.4, 120.2, 119.1, 93.3, 81.6, 66.6, 28.5, 26.6, 21.4, 21.3, 13.4 (5-hydroxy-3'-methyl-5'-oxo-1,1'-diphenyl-3-(trifluoromethyl)-1',5'-dihy-dro-1H,4'H-[4,4'-bipyrazol δ 174. 1, 160.7, 155.8, 139.9, 139.7, 138.2, 130.2, 129.9, 129.6, 127.8, 126.0, 124.4, 124.0, 122.8, 120.4, 88.2, 81.6, 30.7, 28.6, 13 -5-hydroxy-3,3'-dimethyl-5'-oxo-1-phenyl-1',5'-dihy-dro-1H,4'H-[4,4'-bipyrazol]-4'-yl) nm] t R 9.46 min (minor), t R 10.45 min (major); IR (capillary): 2977, 2927, 2098, 1716, 1601, 1488, 138.2, 136.4, 131.2, 130.4, 129.9, 128.3, 123.0, 121.2, 120.4, 95.0, 81.7, 66.3, 28.5, 13.6, 11.7 (5-hydroxy-3,3'-dimethyl-5'-oxo-1-phenyl-1'-(p-tolyl)-1',5'-dihydro-1H, 4'H-[4,4'-bipyrazol]-4'-yl) 11.82 min (minor), t R 12.16 min (major); IR (capillary) 2977, 2925, 2087, 1715, 1611, 1491, 1395, 1363, 1309, 1278, 1254, 1159, 1121, 1176, 1020, 969, 937, 889, 818, 758, 729, 686 161.3, 155.9, 155.3, 146.9, 136.9, 136.4, 136.3, 130.4, 130.3, 128.3, 123.1, 120.3, 119.2, 95.0, 81.7, 66.4, 28.6, 21.0, 13.4, 11.5 3'-ethyl-5-hydroxy-3-methyl-5'-oxo-1,1'-diphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 2977, 2934, 2321, 2097, 1715, 1597, 1490, 1392, 1367, 1306, 1248, 1159, 1075, 1044, 1021, 933, 888, 835, 755, 688 3, 164.2, 162.7, 154.3, 146.1, 137.8, 135.6, 129.2, 129.1, 126.5, 125.7, 121.0, 120.5, 119.2, 118.1, 95.2, 80.4, 69.9, 28.2, 20.9, 11.5, 9 (5-hydroxy-3'-isopropyl-3-methyl-5'-oxo-1,1'-diphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol 2974, 2931, 2107, 1715, 1597, 1490, 1369, 1305, 1249, 1160, 1078, 1023, 979, 899, 834, 755, 689, 660 155.7, 146.1, 139.4, 139.4, 136.3, 130.5, 129.9, 128.4, 126.4, 123.1, 120.1, 119.1, 95.0, 81.6, 66.8, 29.6, 28.6, 28.4, 21.3 2977, 2932, 2097, 1713, 1595, 1492, 1393, 1362, 1305, 1254, 1158, 1073, 1029, 953, 885, 838, 794, 755, 690 2, 167.7, 163.0, 155.6, 145.7, 139.3, 136.3, 130.5, 130.1, 129.9, 128.5, 126.4, 126.2, 123.3, 120.0, 119.0, 95.7, 81.5, 66.9, 37.0, 29.5, 29.3, 28.6, 28.4, 10.9 (5-hydroxy-3-methyl-5'-oxo-1,1',3'-triphenyl-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol]-4'-yl) 2977, 2929, 2098, 1717, 1597, 1490, 1371, 1292, 1254, 1156, 1115, 1074, 1023, 949, 917, 878, 837, 796, 756, 688 5, 162.5, 157.7, 155.8, 146.1, 139.3, 136.2, 131.9, 130.4, 130.0, 129.9, 128.4, 127.7, 126.7, 123.2, 120.3, 119.4, 95.5, 81.7, 65.8, 28.5, 28.3, 11.2; MS (EI) General procedure for the acylation of product 5. In a 10 mL reaction tube equipped with a magnetic stirring bar, the amino-bis-pyrazolone 5 (1 equiv., 0.1 mmol) was stirred in dichloromethane (1.0 mL) at room temprature followed by the addition of Ac 2 O (2.0 equiv. 0.2 mmol) and triethylamine (0.3 equiv., 0.03 mmol). The stirring was continued for 3 hours at room temperature and the crude product was directly purified by flash column chromatography (n-hexane/EtOAc, 3:1) to afford the enolacetate product 6.
tert-Butyl (S)-(1-(4-chlorophenyl)-5-hydroxy-3,3'-dimethyl-5'-oxo-1'-phenyl-1',5'-dihydro-1H,4'H-
tert-Butyl (S)-(5-hydroxy-3,3'-dimethyl-5'-oxo-1'-phenyl-1-(p-tolyl)-1',5'-dihydro-1H,4'H-[4,4'-bipyrazol]-4'-yl)carbamate
tert-Butyl (S)-
tert-Butyl (S)-(
tert-Butyl (S)-
tert-Butyl (S)-(1'-(4-chlorophenyl)
tert-Butyl (S)-
tert-Butyl (S)-(
tert-Butyl (S)-
(S) [1] [2] [3] [4] 7, 166.7, 159.2, 153.8, 146.8, 141.5, 138.2, 137.3, 129.4, 129.0, 128.3, 125.1, 123.5, 118.7, 101.4, 64.5, 28.2, 20.1, 15.0, 14 (S) [1] [2] [3] [4] 0, 166.7, 162.8, 146.6, 141.5, 138.4, 137.3, 129.4, 129.0, 128.3, 125.1, 101.8, 64.5, 28.4, 28.2, 21.5, 20.1, 15.0, 9.5 (S) [1] [2] [3] [4] 9, 166.6, 165.4, 153.9, 146.2, 141.6, 138.3, 137.3, 129.4, 129.0, 128.3, 125.0, 123.5, 118.6, 101.8, 53.6, 28.4, 28.2, 21.0, 20.8, 20.1, 14.9 General procedure for the synthesis of 8 and ent-8. In a 10 mL reaction tube equipped with a magnetic stirring bar, the imine 4a (1.1 equiv., 0.22 mmol), catalyst C-2 or C-5 (2 mol%) and 4 Å molecular sieves (50 mg) were stirred in dichloromethane (1.0 mL) at -48 °C. After 10 minutes, pyrazolone 7 (1.0 equiv. 0.2 mmol) was added and the stirring was continued for 24 hours at the same temperature. The reaction mixture was kept at room temperature for 1 hour and the crude product was directly purified by flash column chromatography (n-hexane/EtOAc, 4:1) to afford the products 8 or 4, 5, 8, 169.7, 155.6, 154.4, 143.6, 137.7, 136.8, 132.2, 130.4, 129.1, 128.9, 128.8, 126.7, 125.3, 120.7, 120.3, 119.3, 99.4, 79.3, 68.3, 52.9, 28.2, 16.4, 16 tert-Butyl ((4S,4'S)-3,3'-dimethyl-5,5'-dioxo-1,1'-diphenyl-4-(prop-2-yn-1-yl)-1',4,5,5'-tetrahydro-1H,4'H-[4,4'-bipyrazol]-4'-yl) 9, 169.7, 156.2, 155.4, 137.4, 136.8, 129.1, 129.0, 126.4, 125.6, 120.4, 119.1, 75.4, 72.6, 67.7, 57.2, 28.2, 20.1, 16.5, 14.7 General procedure for the synthesis of 9. In a 10 mL reaction tube equipped with a magnetic stirring bar, the imine 4a (1.1 equiv., 0.22 mmol), catalyst C-2 (1 mol%) and 4 Å molecular sieves (50 mg) were stirred in dichloromethane (1.0 mL) at -48 °C. After 10 minutes, pyrazolone 1a (1.0 equiv. 0.2 mmol) was added and the stirring was continued for 24 hours at the same temperature. The reaction mixture was warmed to the room temperature. After 1 hour NFSI or NCS (1.5 equiv.) and K 2 CO 3 (1.5 equiv.) were added and the reaction mixture was stirred for 3.5 hours at the room temperature. The crude product was directly purified by flash column chromatography (nhexane/EtOAc, 4:1) to afford the products 9a or 9b.
ent
tert-Butyl ((4R,4'S)-4-fluoro-3,3'-dimethyl-5,5'-dioxo-1,1'-diphenyl-1',4,5,5'-tetrahydro-1H,4'H-[4,4'-bipyrazol 1, 164.7, 156.7, 154.0, 152.2, 137.5, 136.2, 129.2, 129.1, 126.7, 125.9, 119.8, 119.2, 89.7, 82.0, 69.0, 28.2, 15.7, 14. 
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